Cellnovo Group, a medical technology company that has developed and markets the first connected all-in-one diabetes management system, announces that Société Générale, acting in the name and on behalf of the Managers, has fully exercised the overallotment option of the 80,000 additional new shares at the offer price of €10.63 per share. Consequently, the total number of Cellnovo shares offered as part of the IPO reaches 3,049,557 new shares.